Adaptive designs of ongoing Phase II-III clinical trials of therapeutic candidates may shorten trial times and result in the use of fewer subjects, which may speed up pass-or-stop decisions premature and allow design changes for a specific test to be coordinated in the international centers where it is performed.
Miundo inayoweza kubadilika ndani ya vipimo vinavyoendelea vya Awamu ya II-II katika matibabu yaliyoteuliwa inaweza kufupisha muda wa majaribio na kutumia wahusika wachache, ikiwezekana kuharakisha maamuzi ya kukamilisha mapema au kufaulu, na kuratibu mabadiliko ya muundo kwa majaribio fulani katika maeneo yake ya kimataifa.